A shortage listing ends. 6 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 4 of 4 of this archive, newest first.
The document is four pages. Three of them are about dates.
Reported from the sessions, and from the two hours afterwards.
Reported from the analysis, not from a warning notice.
Follow the resin, not the catalogue.
The evidence base is thin and the document says so, which is to its credit.
A proper account of an operation that existed, and of what closing it cost.
Efficacy was never the question in this appraisal. Duration of treatment was.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The evidence base is thin and the document says so, which is to its credit.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The result is unremarkable. What the report omits is not.
The document is four pages. Three of them are about dates.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Reported from the analysis, not from a warning notice.
Reported from the sessions, and from the two hours afterwards.
The route did not close because of a rule about peptides.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Reported from the analysis, not from a warning notice.
A proper account of an operation that existed, and of what closing it cost.
The document is four pages. Three of them are about dates.